Fig. 10
From: Zoledronic acid blocks the interaction between breast cancer cells and regulatory T-cells
Inhibition of C.M. of MDA-MB-231 induced migration of Tregs following treatment with monoclonal antibody of CCL2 or CCL5. C.M. with or without addition of anti-CCL2 antibody (10 μg/ml), anti-CCL5 antibody (20 μg/ml), alone or in combination on the migration of Tregs was applied. The relative percentages of migrated cells were compared with that of C.M. of MDA-MB-231 cells without monoclonal antibody (control). Values indicate means ± SEM of results from three independent experiments. Significant differences were compared using one-way ANOVA; ** P < 0.01; *** P < 0.001